Alpha Cognition Begins Patient Enrollment in ZUNVEYL RESOLVE Study
Alpha Cognition announced the enrollment of the first patient in RESOLVE, a Phase 4 post-marketing clinical study designed to further evaluate the tolerability profile and treatment experience associated with ZUNVEYL in routine clinical practice. The RESOLVE study is expected to enroll approximately 150 patients across multiple clinical sites and will monitor adverse events, treatment persistence, and discontinuation rates throughout the study. Data generated from RESOLVE is expected to complement findings from previous clinical studies and contribute to the growing body of evidence supporting the use of ZUNVEYL in clinical practice.
